Gyre Therapeutics (GYRE) Current Deferred Revenue (2010 - 2025)
Gyre Therapeutics (GYRE) reported Current Deferred Revenue of $14000.0 for Q4 2025, down 77.05% year-over-year from $61000.0 in Q4 2024, and down 75.86% quarter-over-quarter from $58000.0 in Q3 2025.
Gyre Therapeutics (GYRE) Current Deferred Revenue (2010 - 2025) Analysis & Trends
Gyre Therapeutics (GYRE) has 15 years of Current Deferred Revenue data on file, last reported at $14000.0 in Q4 2025.
- Current Deferred Revenue for Q4 2025 came in at $14000.0, down 77.05% year-over-year; the trailing twelve-month figure through Dec 2025 was $14000.0 (down 77.05% YoY), and the FY2025 annual result was $14000.0, down 77.05% from the prior year.
- Current Deferred Revenue fell to $14000.0 in Q4 2025 per GYRE's latest filing, from $58000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $2.0 million in Q2 2021 and troughed at $14000.0 in Q4 2025.
- A 5-year average of $378923.1 and a median of $58000.0 in 2025 frame the typical range for Current Deferred Revenue.
- On a YoY basis, Current Deferred Revenue climbed as much as 517.58% in 2021 and fell as far as 88.4% in 2021.
- A 5-year view of Current Deferred Revenue shows it stood at $230000.0 in 2021, then plunged by 36.96% to $145000.0 in 2022, then plunged by 73.1% to $39000.0 in 2023, then jumped by 56.41% to $61000.0 in 2024, then tumbled by 77.05% to $14000.0 in 2025.
- Business Quant data shows GYRE's Current Deferred Revenue at $14000.0 in Q4 2025, $58000.0 in Q3 2025, and $28000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 58,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 61,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Dec 31, 2023 | 39,000.00 |
| Dec 31, 2022 | 145,000.00 |
| Dec 31, 2021 | 230,000.00 |
| Sep 30, 2021 | 853,000.00 |
| Jun 30, 2021 | 2.04 Mn |
| Mar 31, 2021 | 1.33 Mn |
| Dec 31, 2020 | 1.98 Mn |
| Sep 30, 2020 | 764,000.00 |
| Jun 30, 2020 | 330,000.00 |
| Dec 31, 2019 | 15.00 Mn |
| Dec 31, 2018 | 15,000.00 |
| Sep 30, 2018 | 13,000.00 |
| Jun 30, 2018 | 10,000.00 |